MedicarePartD.guide

A non-government resource built from CMS public data

IL-17, IL-23 and IL-12/23 biologics on every 2026 New Mexico Part D plan

Pick a drug class, or type the drugs you want to check, and see which of the 11 stand-alone Part D plans in New Mexico cover each one, on what tier, and with what restrictions.

A class overrides typed names. Separate names with commas; brand or generic both work.

  • Covered
  • Covered, needs prior authorization (PA) or step therapy (ST)
  • Not on the formulary
  • QL 60/30d = quantity limit, 60 units per 30 days

11 plans, cheapest premium first. Scroll sideways for all of them →

IL-17, IL-23 and IL-12/23 biologics by 2026 New Mexico Part D plan
DrugWellcare Classic$0.00/moS4802-090Wellcare Value Script$0.00/moS4802-159HealthSpring Assurance Rx$0.00/moS5617-128Humana Basic Rx Plan$0.00/moS5884-110AARP Medicare Rx Saver from UHC$0.00/moS5921-371Humana Value Rx Plan$69.60/moS5884-205Humana Premier Rx Plan$75.60/moS5884-172AARP Medicare Rx Preferred from UHC$82.30/moS5921-407SilverScript Choice$104.00/moS5601-052Blue Cross MedicareRx Value$111.30/moS5715-020Blue Cross MedicareRx Basic$145.40/moS5715-013
StelaraustekinumabNot coveredNot coveredTier 5PA25%QL 0.5/28dTier 5PA25%QL 1.5/84dNot coveredTier 5PA26%QL 1.5/84dTier 5PA33%QL 1.5/84dNot coveredTier 5PA25%QL 0.5/28dNot coveredNot covered
ustekinumab biosimilarsWezlana, Selarsdi, Pyzchiva and othersNot coveredNot coveredTier 5PA25%QL 0.5/28dTier 5PA25%QL 1.5/84dNot coveredTier 5PA26%QL 1.5/84dTier 5PA33%QL 1.5/84dNot coveredTier 5PA25%QL 0.5/28dNot coveredNot covered
Wezlanaustekinumab-auubNot coveredNot coveredNot coveredNot coveredNot coveredNot coveredNot coveredNot coveredNot coveredNot coveredNot covered
Selarsdiustekinumab-aeknNot coveredNot coveredTier 3PA25%QL 0.5/28dNot coveredNot coveredNot coveredNot coveredNot coveredNot coveredNot coveredNot covered
SkyrizirisankizumabTier 5PA25%QL 6/365dTier 5PA25%QL 6/365dTier 5PA25%QL 2/28dTier 5PA25%QL 2/84dTier 5PA25%QL 1/28dTier 5PA26%QL 2/84dTier 5PA33%QL 2/84dTier 5PA31%QL 1/28dTier 5PA25%QL 6/365dTier 5PA25%QL 6/365dTier 5PA25%QL 6/365d
TremfyaguselkumabTier 5PA25%QL 2/28dTier 5PA25%QL 2/28dTier 5PA25%QL 2/28dTier 5PA25%QL 3/84dTier 5PA25%Tier 5PA26%QL 3/84dTier 5PA33%QL 3/84dTier 5PA31%Tier 5PA25%QL 1/28dTier 5PA25%QL 3/56dTier 5PA25%QL 3/56d
CosentyxsecukinumabTier 5PA25%QL 10/28dTier 5PA25%QL 10/28dTier 5PA25%QL 10/28dTier 5PA25%QL 8/28dTier 5PA25%QL 10/30dTier 5PA26%QL 8/28dTier 5PA33%QL 8/28dTier 5PA31%QL 10/30dNot coveredTier 5PA25%QL 8/28dTier 5PA25%QL 8/28d
TaltzixekizumabNot coveredNot coveredNot coveredNot coveredNot coveredNot coveredNot coveredNot coveredNot coveredNot coveredNot covered
BimzelxbimekizumabNot coveredNot coveredNot coveredNot coveredNot coveredNot coveredNot coveredNot coveredTier 5PA25%QL 4/28dNot coveredNot covered

Where a plan covers several strengths or forms of a drug, the cell shows the least restricted one. Costs are the 30-day preferred-pharmacy cost-sharing in the initial coverage phase, from the CMS 2026 formulary files. Click a plan for its full drug list.